Mundipharma will distribute Grünenthal’s analgesic in China

| By | Analgesics, China, Pharmaceutical Distribution
0
727

Grünenthal and Mundipharma announced today that they have entered into a License and Distribution Agreement. Under its terms, Mundipharma will market and distribute Grünenthal’s Tramal® (tramadol) in China from May 1, 2018.

Developed by Grünenthal, Tramal is a well-established analgesic for the treatment of moderate to severe pain. It is the only international brand of tramadol in China that includes sustained release tablets and immediate release capsules, as well as an intravenous formulation used for post-operative pain in patient controlled intravenous analgesia (PCIA). Delivering the analgesic intravenously with a patient-controlled device can provide an important and effective pain control option for patients.

“The addition of Tramal to our portfolio reinforces Mundipharma’s position as the international leader in advancing appropriate cancer-related pain relief in China,” says Raman Singh, CEO Mundipharma. “PCIA is an advanced option for medical professionals to treat patients suffering from moderate to severe pain. We are pleased to extend our relationship with Grünenthal to advance the treatment of patients in China, where there remains an unmet patient need,” he adds. “Both organisations are committed to ensuring the responsible use of analgesic medications to treat post-operative patients when other options provide insufficient relief.”

Mundipharma is a network of independent associated companies which are privately owned entities covering pharmaceutical markets in Asia-Pacific, Latin America, Middle East and Africa. The headquarters for these territories is in Singapore.

Grünenthal is an independent, family-owned company headquartered in Aachen, Germany. The Grünenthal Group is an entrepreneurial, science-based pharmaceutical company specialized in pain, gout and inflammation.

SOURCE: grunenthal
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.